Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.

Shiao-Pei WeathersJulie Rood-BreithauptJohn de GrootGail ThomasMarianna ManfriniMarta Penas-PradoVinay K PuduvalliChristian ZwingelsteinW K Alfred Yung

Published in: Neuro-oncology advances (2021)

High-dose macitentan was well tolerated in recurrent GBM patients concomitantly receiving TMZ. TEAEs were consistent with those seen in patients receiving either drug individually.

Keyphrases

high dose
newly diagnosed
end stage renal disease
pulmonary arterial hypertension
ejection fraction
chronic kidney disease
low dose
clinical trial
prognostic factors
peritoneal dialysis
study protocol
randomized controlled trial
patient reported outcomes
phase iii
patient reported
drug induced
smoking cessation